Kate J. Newberry

ORCID: 0000-0001-9294-5965 · 1 paper in corpus · active 2016

Study types

  • article 1
article 2016
·doi:10.1182/blood.v128.22.478.478

Abstract Introduction: Anemia is common in MPN-associated myelofibrosis (MF), and current therapies (e.g., erythropoiesis stimulating agents, androgens, danazol, immune modulatory drugs and corticosteroids) are unsatisfactory. Furthermore, …